Quote | Wuxi AppTec Co. Ltd. ADR (OTCMKTS:WUXAY)
Last: | $3.76 |
---|---|
Change Percent: | -2.91% |
Open: | $3.6843 |
Close: | $3.76 |
High: | $3.76 |
Low: | $3.6843 |
Volume: | 1,170 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Wuxi AppTec Co. Ltd. ADR (OTCMKTS:WUXAY)
2024-06-17 13:24:05 ET More on WuXi AppTec More On WuXi, And It Isn't Good Historical earnings data for WuXi AppTec Dividend scorecard for WuXi AppTec Financial information for WuXi AppTec Read the full article on Seeking Alpha For further det...
2024-05-29 12:00:00 ET Summary Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affi...
Message Board Posts | Wuxi AppTec Co. Ltd. ADR (OTCMKTS:WUXAY)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Wuxi AppTec Co. Ltd. ADR Company Name:
WUXAY Stock Symbol:
OTCMKTS Market:
WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations PR Newswire Revenue Reached RMB7,982 Million ; Excluding COVID-19 Commercial Projects, Down 1.8% Net Profit Attributable to the Owners of the Company Reached...
WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time PR Newswire Revenue Up 2.5% Year-over-Year to RMB40,341 Million ; Excluding COVID-19 Commercial Projects, Up 25.6% Net Profit Attributa...
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma PR Newswire AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval for a solid tumor cancer. ...